Recombinant therapeutic protein vaccines

Protein and Peptide Letters

Volumn 20, Issue 12, 2013, Pages 1324-1344

  Ohtake, Satoshi ^a   Arakawa, Tsutomu ^a,b  

^a PFIZER INC   (United States)

^b ALLIANCE PROTEIN LABORATORIES   (United States)

Author keywords

Expression systems; Recombinant proteins; Therapeutic proteins; Vaccines

Indexed keywords

ANTHRAX VACCINE; BCG VACCINE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; CANCER VACCINE; CHOLERA VACCINE; CYTOMEGALOVIRUS VACCINE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; MELANOMA ANTIGEN 3; MENINGITIS VACCINE; MONOCLONAL ANTIBODY; NANOCAPSULE; NY ESO 1 ANTIGEN; PERTUSSIS VACCINE; PSEUDOMONAS VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TUMOR ANTIGEN; VIRUS DNA; VIRUS VECTOR; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTHRAX; ANTIGEN EXPRESSION; ARTICLE; BACILLUS ANTHRACIS; BACTERIUM IDENTIFICATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CHOLERA; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; LUNG INFECTION; LUNG NON SMALL CELL CANCER; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENINGITIS; MOLECULAR DYNAMICS; NEISSERIA MENINGITIDIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PARTICLE SIZE; PERTUSSIS; PLASMODIUM FALCIPARUM; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SACCHAROMYCES CEREVISIAE; TUBERCULOSIS; UTERINE CERVIX CANCER; VACCINE PRODUCTION; VIRUS IDENTIFICATION; VIRUS LIKE AGENT; ANIMAL; BIOTECHNOLOGY; CHO CELL LINE; CRICETULUS; HAMSTER; MOUSE;

BACTERIA (MICROORGANISMS);

ANIMALS; BIOTECHNOLOGY; CHO CELLS; CRICETINAE; CRICETULUS; ESCHERICHIA COLI; HUMANS; MICE; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 84887981891     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986652012131112122245     Document Type: Article

References (314)

1. WHO: Recommendations for the production, http://www.who.int/ bloodproducts.
2. Burnouf, T. Modern plasma fractionation. Transfus Med. Rev., 2007, 21(2), 101-17.
3. Shankar, G.; Pendley, C.; Stein, K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses againstbiological drugs. Nat. Biotechnol., 2007, 25(5), 555-61.
4. Ofosu, F.A.; Freedman, J.; Semple, J.W. Plasma-derived biologicalmedicines used to promote haemostasis. Thromb. Haemost., 2008, 99(5), 851-62.
5. Putnam, F.W. In: The Plasma Proteins, Structure, Function, and Genetic Control, Putnam, F.W., Ed. Academic Press: Orlando, FL, 1984; Vol. IV, pp 45-166.
6. Burnouf, T. Chromatography in plasma fractionation: benefits andfuture trends. J. Chromatogr. B Biomed. Appl., 1995, 664(1), 3-15.
7. Okuda, M.; Uemura, Y.; Tatsumi, N. A new method of purifyingfibrinogen with both biological and immunological activity fromhuman plasma. Prep. Biochem. Biotechnol., 2003, 33(4), 239-52.
8. Itakura, K.; Hirose, T.; Crea, R.; Riggs, A.D.; Heyneker, H.L.; Bolivar, F.; Boyer, H. W. Expression in Escherichia coli of achemically synthesized gene for the hormone somatostatin. Science, 1977, 198(4321), 1056-63.
9. Goeddel, D.V.; Kleid, D.G.; Bolivar, F.; Heyneker, H.L.; Yansura, D.G.; Crea, R.; Hirose, T.; Kraszewski, A.; Itakura, K.; Riggs, A.D. Expression in Escherichia coli of chemically synthesized genes forhuman insulin. Proc. Natl. Acad. Sci. USA, 1979, 76(1), 106-10.
10. Wetzel, R.; Kleid, D.G.; Crea, R.; Heyneker, H.L.; Yansura, D.G.; Hirose, T.; Kraszewski, A.; Riggs, A.D.; Itakura, K.; Goeddel, D.V. Expression in Escherichia coli of a chemically synthesizedgene for a "mini-C" analog of human proinsulin. Gene, 1981, 16(1-3), 63-71.
11. Steinberg, F. M.; Raso, J. Biotech pharmaceuticals and biotherapy:an overview. J. Pharm. Pharm. Sci., 1998, 1(2), 48-59.
12. Wraith, J.E. Lysosomal disorders. Semin. Neonatol., 2002, 7(1), 75-83.
13. Barton, N.W.; Furbish, F.S.; Murray, G.J.; Garfield, M.; Brady, R.O. Therapeutic response to intravenous infusions ofglucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. USA, 1990, 87(5), 1913-6.
14. Kornfeld, S. Lysosomal enzyme targeting. Biochem. Soc. Trans., 1990, 18(3), 367-74.
15. Kornfeld, S. Trafficking of lysosomal enzymes. FASEB J., 1987, 1(6), 462-8.
16. Grubb, J.H.; Vogler, C.; Sly, W.S. New strategies for enzymereplacement therapy for lysosomal storage diseases. RejuvenationRes., 2010, 13(2-3), 229-36.
17. Wurm, F.M. Production of recombinant protein therapeutics incultivated mammalian cells. Nat. Biotechnol., 2004, 22(11), 1393-8.
18. Miller, M. To build a better mousetrap, use human parts. J. Natl. Cancer Inst., 1998, 90(1), 14-6.
19. Targan, S.R.; Hanauer, S.B.; van Deventer, S.J.; Mayer, L.; Present, D.H.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; Rutgeerts, P.J. A short-term study of chimeric monoclonal antibodycA2 to tumor necrosis factor alpha for Crohn's disease. Crohn'sDisease cA2 Study Group. N. Engl. J. Med., 1997, 337(15), 1029-35.
20. Yamada, T. Therapeutic monoclonal antibodies. Keio J. Med., 2011, 60(2), 37-46.
21. Lambo, T.A. Eradication of smallpox. N. Engl. J. Med., 1981, 305(4), 224.
22. Fenner, F. A successful eradication campaign. Global eradicationof smallpox. Rev. Infect. Dis., 1982, 4(5), 916-30.
23. Wells, T.N.; Alonso, P.L.; Gutteridge, W.E. New medicines toimprove control and contribute to the eradication of malaria. Nat. Rev. Drug Discov., 2009, 8(11), 879-91.
24. Meissner, H.C.; Strebel, P.M.; Orenstein, W.A. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics, 2004, 114(4), 1065-9.
25. Preston, N.W. Eradication of poliomyelitis. Lancet, 2005, 366(9492), 1164.
26. Bitter, G.A.; Egan, K.M.; Burnette, W.N.; Samal, B.; Fieschko, J.C.; Peterson, D.L.; Downing, M.R.; Wypych, J.; Langley, K.E. Hepatitis B vaccine produced in yeast. J. Med. Virol., 1988, 25(2), 123-40.
27. Cai, K.; Gierman, T.M.; Hotta, J.; Stenland, C.J.; Lee, D.C.; Pifat, D.Y.; Petteway, S.R., Jr. Ensuring the biologic safety of plasmaderived therapeutic proteins: detection, inactivation, and removal ofpathogens. BioDrugs, 2005, 19(2), 79-96.
28. Rothstein, F. Differential precipitation of proteins. Science andtechnology. Bioprocess Technol., 1994, 18, 115-208.
29. Arakawa, T.; Kita, Y.; Timasheff, S.N. Protein precipitation anddenaturation by dimethyl sulfoxide. Biophys. Chem., 2007, 131(1-3), 62-70.
30. Scandella, D.; Gilbert, G.E.; Shima, M.; Nakai, H.; Eagleson, C.; Felch, M.; Prescott, R.; Rajalakshmi, K.J.; Hoyer, L.W.; Saenko, E. Some factor VIII inhibitor antibodies recognize a common epitopecorresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood, 1995, 86(5), 1811-9.
31. Wight, J.; Paisley, S. The epidemiology of inhibitors inhaemophilia A: a systematic review. Haemophilia, 2003, 9(4), 418-35.
32. Zimmerman, T.S.; Ratnoff, O.D.; Powell, A.E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and vonWillebrand's dissase, with observations on combined deficienciesof antihemophilic factor and proaccelerin (factor V) and on anacquired circulating anticoagulant against antihemophilic factor. J. Clin. Invest., 1971, 50(1), 244-54.
33. Giannelli, F.; Choo, K.H.; Rees, D.J.; Boyd, Y.; Rizza, C.R.; Brownlee, G.G. Gene deletions in patients with haemophilia B andanti-factor IX antibodies. Nature, 1983, 303(5913), 181-2.
34. Goudemand, J.; Peynet, J.; Chambost, H.; Negrier, C.; Briquel, M.E.; Claeyssens, S.; Derlon-Borel, A.; Guerois, C.; Caron, C.; Scherrmann, J.M.; Debray, M.; Bridey, F. A cross-overpharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Thromb. Haemost., 1998, 80(6), 919-24.
35. Burnouf, T.; Michalski, C.; Goudemand, M.; Huart, J.J. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography. Vox Sang, 1989, 57(4), 225-32.
36. Hampton, K.K.; Preston, F.E.; Lowe, G.D.; Walker, I. D.; Sampson, B. Reduced coagulation activation following infusion ofa highly purified factor IX concentrate compared to a prothrombincomplex concentrate. Br. J. Haematol., 1993, 84(2), 279-84.
37. Keeling, D.; Tait, C.; Makris, M. Guideline on the selection anduse of therapeutic products to treat haemophilia and otherhereditary bleeding disorders. A United Kingdom HaemophiliaCenter Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia, 2008, 14(4), 671-84.
38. Valentino, L.A.; Oza, V.M. Blood safety and the choice of antihemophilicfactor concentrate. Pediatr. Blood Cancer, 2006, 47(3), 245-54.
39. Salomon, O.; Seligsohn, U. New observations on factor XI deficiency. Haemophilia, 2004, 10(Suppl 4), 184-7.
40. Gootenberg, J.E. Factor concentrates for the treatment of factorXIII deficiency. Curr. Opin. Hematol., 1998, 5(6), 372-5.
41. Berger, A. Human albumin administration in critically ill patients:systematic review of randomised controlled trials. BMJ, 1998, 317, 235-240.
42. Chuang, V.T.; Kragh-Hansen, U.; Otagiri, M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res., 2002, 19(5), 569-77.
43. Fernandez-San Millan, A.; Mingo-Castel, A.; Miller, M.; Daniell, H. A chloroplast transgenic approach to hyper-express and purifyHuman Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol. J., 2003, 1(2), 71-9.
44. Berezenko, S. Heterogeneity and oxidation status of commercialhuman albumin preparations in clinical use. Crit. Care Med., 2006, 34(4), 1291.
45. Chuang, V.T.; Otagiri, M. Recombinant human serum albumin. Drugs Today (Barc), 2007, 43(8), 547-61.
46. Otagiri, M.; Chuang, V.T. Pharmaceutically important pre- andposttranslational modifications on human serum albumin. Biol. Pharm. Bull., 2009, 32(4), 527-34.
47. Kragh-Hansen, U.; Donaldson, D.; Jensen, P.H. The glycanstructure of albumin Redhill, a glycosylated variant of humanserum albumin. Biochim. Biophys. Acta, 2001, 1550(1), 20-6.
48. Imbach, P.; Barandun, S.; d'Apuzzo, V.; Baumgartner, C.; Hirt, A.; Morell, A.; Rossi, E.; Schoni, M.; Vest, M.; Wagner, H.P. Highdoseintravenous gammaglobulin for idiopathic thrombocytopenicpurpura in childhood. Lancet, 1981, 1(8232), 1228-31.
49. Pirofsky, B.; Kinzey, D. M. Intravenous immune globulins. Areview of their uses in selected immunodeficiency and autoimmunediseases. Drugs, 1992, 43(1), 6-14.
50. Rudolph, R.; Lilie, H. In vitro folding of inclusion body proteins. FASEB J., 1996, 10(1), 49-56.
51. Clark, E.D.B. Refolding of recombinant proteins. Curr OpinBiotechnol, 1998, 9(2), 157-63.
52. Tsumoto, K.; Ejima, D.; Kumagai, I.; Arakawa, T. Practical considerations in refolding proteins from inclusion bodies. ProteinExpr. Purif., 2003, 28(1), 1-8.
53. Clark, E.D.P.; Schwarz, E.; Rudolph, R. Inhibition of aggregationside reactions during in vitro protein folding. Methods Enzymol., 1999, 309, 217-236.
54. Rudolph, R.; Fisher, S. Process for obtaining renatured proteins.1990, US4933434 A.
55. Reddy, K.R.; Lilie, H.; Rudolph, R.; Lange, C. L-Arginineincreases the solubility of unfolded species of hen egg whitelysozyme. Protein Sci., 2005, 14(4), 929-35.
56. Arakawa, T.; Tsumoto, K. The effects of arginine on refolding ofaggregated proteins: not facilitate refolding, but suppressaggregation. Biochem. Biophys. Res. Commun., 2003, 304(1), 148-52.
57. Tsumoto, K.; Ejima, D.; Kita, Y.; Arakawa, T. Review: Why isarginine effective in suppressing aggregation? Protein Pept. Lett., 2005, 12(7), 613-9.
58. Arakawa, T.; Kita, Y.; Ejima, D.; Tsumoto, K.; Fukada, H. Aggregation suppression of proteins by arginine during thermalunfolding. Protein Pept. Lett., 2006, 13(9), 921-7.
59. Arakawa, T.; Ejima, D.; Tsumoto, K.; Obeyama, N.; Tanaka, Y.; Kita, Y.; Timasheff, S.N. Suppression of protein interactions byarginine: a proposed mechanism of the arginine effects. Biophys. Chem., 2007, 127(1-2), 1-8.
60. Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Philo, J.S.; Arakawa, T. Role of arginine in protein refolding, solubilization, and purification. Biotechnol. Prog., 2004, 20(5), 1301-8.
61. Tetala, K.K.; Van Beek, T.A. Bioaffinity chromatography inmonolithic supports. J. Sep. Sci., 2011, 33, 422-438.
62. Schoenmakers, P. Chromatography in industry. Annu. Rev. Anal. Chem. (Palo Alto Calif), 2009, 2, 333-57.
63. Gagnon, P.; Cheung, C.W.; Yazaki, P.J. Cooperative multimodalretention of IgG, fragments, and aggregates on hydroxyapatite. J. Sep. Sci., 2009, 32(22), 3857-65.
64. Gagnon, P. Monoclonal antibody purification with hydroxyapatite. N. Biotechnol., 2009, 25(5), 287-93.
65. Jiang, Z.; Smith, N.W.; Liu, Z. Preparation and application ofhydrophilic monolithic columns. J. Chromatogr. A, 2011, 1218(17), 2350-61.
66. Yigzaw, Y.; Shukla, A.A. Modes of Preparative Chromatography. In: Process Scale Bioseparations for the Biopharmaceutical Industry, Shukla, A.A.; Etzel, M.R.; Gadam, S.; Ed. CRC Press:Boca Raton, FL, 2007; pp 179-226.
67. Goldblatt, J.; Fletcher, J.M.; McGill, J.; Szer, J.; Wilson, M. Enzyme replacement therapy "drug holiday": results from anunexpected shortage of an orphan drug supply in Australia. BloodCells Mol. Dis., 2011, 46(1), 107-10.
68. von Behring, E.A.; Kitasato, S. Uber das Zustandekommen derDihtherie-Immunitat und der Tetanus Immunitat bei Thieren. DtschMe Wochenschr, 1890, 16, 1113-1114.
69. Bruton, O.C. Agammaglobulinemia. Pediatrics, 1952, 9(6), 722-8.
70. Casadevall, A.; Scharff, M.D. Return to the past: the case forantibody-based therapies in infectious diseases. Clin. Infect. Dis., 1995, 21(1), 150-61.
71. Kohler, G.; Milstein, C. Continuous cultures of fused cellssecreting antibody of predefined specificity. Nature, 1975, 256(5517), 495-7.
72. Queen, C.; Schneider, W.P.; Selick, H.E.; Payne, P.W.; Landolfi, N.F.; Duncan, J.F.; Avdalovic, N.M.; Levitt, M.; Junghans, R.P.; Waldmann, T.A. A humanized antibody that binds to theinterleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 1989, 86(24), 10029-33.
73. Ellis, R.W. New Vaccine Technologies. Eurekah.com/LandesBioscience: Georgetown, TX, 2001.
74. Fernandez-Robledo, J.A.; Vasta, G.R. Production of recombinantproteins from protozoan parasites. Trends Parasitol, 26(5), 244-54.
75. Hillier, C.J.; Ware, L.A.; Barbosa, A.; Angov, E.; Lyon, J.A.; Heppner, D.G.; Lanar, D.E. Process development and analysis ofliver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun., 2005, 73(4), 2109-15.
76. Arnot, D.E.; Cavanagh, D.R.; Remarque, E.J.; Creasey, A.M.; Sowa, M.P.; Morgan, W.D.; Holder, A.A.; Longacre, S.; Thomas, A.W. Comparative testing of six antigen-based malaria vaccinecandidates directed toward merozoite-stage Plasmodiumfalciparum. Clin. Vaccine Immunol., 2008, 15(9), 1345-55.
77. Hilleman, M.R.; Bertland, A.U.; Buynak, E.B.; Lampson, G.P.; MaAleer, W.J.; McLean, A.A.; Roehn, R.R.; Tytell, A.A. Clinical and laboratory studies of HBsAg vaccine. In: Viral hepatitis, Vyas, G.N.; Coeh, S.N.; Schmidt, R. Eds. Franklin Institute Press:Philadelphia, 1978; pp 525-537.
78. Valenzuela, P.; Medina, A.; Rutter, W.J.; Ammerer, G.; Hall, B.D. Synthesis and assembly of hepatitis B virus surface antigenparticles in yeast. Nature, 1982, 298(5872), 347-50.
79. Kuroda, S.; Itoh, Y.; Miyazaki, T.; Otaka-Imai, S.; Fujisawa, Y. Efficient expression of genetically engineered hepatitis B virussurface antigen P31 proteins in yeast. Gene, 1989, 78(2), 297-308.
80. Kuroda, S.; Otaka, S.; Miyazaki, T.; Nakao, M.; Fujisawa, Y. Hepatitis B virus envelope L protein particles. Synthesis andassembly in Saccharomyces cerevisiae, purification andcharacterization. J. Biol. Chem., 1992, 267(3), 1953-61.
81. Yamada, T.; Iwasaki, Y.; Tada, H.; Iwabuki, H.; Chuah, M.K.; VandenDriessche, T.; Fukuda, H.; Kondo, A.; Ueda, M.; Seno, M.; Tanizawa, K.; Kuroda, S. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol., 2003, 21(8), 885-90.
82. Stephenne, J. Recombinant versus plasma-derived hepatitis Bvaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine, 1988, 6(4), 299-303.
83. Thanavala, Y.; Yang, Y.F.; Lyons, P.; Mason, H.S.; Arntzen, C. Immunogenicity of transgenic plant-derived hepatitis B surfaceantigen. Proc. Natl. Acad. Sci. USA, 1995, 92(8), 3358-61.
84. Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a bloodbornenon-A, non-B viral hepatitis genome. Science, 1989, 244(4902), 359-62.
85. Tam, A.W.; Smith, M.M.; Guerra, M.E.; Huang, C.C.; Bradley, D.W.; Fry, K.E.; Reyes, G.R. Hepatitis E virus (HEV): molecularcloning and sequencing of the full-length viral genome. Virology, 1991b 185(1), 120-31.
86. Pizza, M.; Scarlato, V.; Masignani, V.; Giuliani, M.M.; Arico, B.; Comanducci, M.; Jennings, G.T.; Baldi, L.; Bartolini, E.; Capecchi, B.; Galeotti, C.L.; Luzzi, E.; Manetti, R.; Marchetti, E.; Mora, M.; Nuti, S.; Ratti, G.; Santini, L.; Savino, S.; Scarselli, M.; Storni, E.; Zuo, P.; Broeker, M.; Hundt, E.; Knapp, B.; Blair, E.; Mason, T.; Tettelin, H.; Hood, D.W.; Jeffries, A.C.; Saunders, N.J.; Granoff, D.M.; Venter, J.C.; Moxon, E.R.; Grandi, G.; Rappuoli, R. Identification of vaccine candidates against serogroup Bmeningococcus by whole-genome sequencing. Science, 2000, 287(5459), 1816-20.
87. Jansen, K.U.; Rosolowsky, M.; Schultz, L.D.; Markus, H.Z.; Cook, J.C.; Donnelly, J.J.; Martinez, D.; Ellis, R.W.; Shaw, A.R. Vaccination with yeast-expressed cottontail rabbit papillomavirus(CRPV) virus-like particles protects rabbits from CRPV-inducedpapilloma formation. Vaccine, 1995, 13(16), 1509-14.
88. Crawford, S.E.; Labbe, M.; Cohen, J.; Burroughs, M.H.; Zhou, Y.J.; Estes, M.K. Characterization of virus-like particles producedby the expression of rotavirus capsid proteins in insect cells. J. Virol., 1994, 68(9), 5945-52.
89. Miyamura, K.; Kajigaya, S.; Momoeda, M.; Smith-Gill, S.J.; Young, N.S. Parvovirus particles as platforms for proteinpresentation. Proc. Natl. Acad. Sci. USA, 1994, 91(18), 8507-11.
90. Remeta, D.P.; Krumbiegel, M.; Minetti, C.A.; Puri, A.; Ginsburg, A.; Blumenthal, R. Acid-induced changes in thermal stability andfusion activity of influenza hemagglutinin. Biochemistry, 2002, 41(6), 2044-54.
91. Terpe, K. Overview of bacterial expression systems forheterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl. Microbiol. Biotechnol., 2006, 72(2), 211-22.
92. Erdile, L.F.; Guy, B. OspA lipoprotein of Borrelia burgdorferi is amucosal immunogen and adjuvant. Vaccine, 1997, 15(9), 988-96.
93. Song, L.; Nakaar, V.; Kavita, U.; Price, A.; Huleatt, J.; Tang, J.; Jacobs, A.; Liu, G.; Huang, Y.; Desai, P.; Maksymiuk, G.; Takahashi, V.; Umlauf, S.; Reiserova, L.; Bell, R.; Li, H.; Zhang, Y.; McDonald, W.F.; Powell, T.J.; Tussey, L. Efficacious recombinant influenza vaccines produced by high yield bacterialexpression: a solution to global pandemic and seasonal needs. PLoSONE, 2008, 3(5), e2257.
94. Brichard, V.G.; Lejeune, D. GSK's antigen-specific cancerimmunotherapy programme: pilot results leading to Phase IIIclinical development. Vaccine, 2007, 25(Suppl 2), B61-71.
95. Masignani, V.; Rappuoli, R.; Pizza, M. Reverse vaccinology: agenome-based approach for vaccine development. Expert Opin. Biol. Ther., 2002, 2(8), 895-905.
96. Vedadi, M.; Lew, J.; Artz, J.; Amani, M.; Zhao, Y.; Dong, A.; Wasney, G.A.; Gao, M.; Hills, T.; Brokx, S.; Qiu, W.; Sharma, S.; Diassiti, A.; Alam, Z.; Melone, M.; Mulichak, A.; Wernimont, A.; Bray, J.; Loppnau, P.; Plotnikova, O.; Newberry, K.; Sundararajan, E.; Houston, S.; Walker, J.; Tempel, W.; Bochkarev, A.; Kozieradzki, I.; Edwards, A.; Arrowsmith, C.; Roos, D.; Kain, K.; Hui, R. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol. Biochem. Parasitol., 2007, 151(1), 100-10.
97. Mehlin, C.; Boni, E.; Buckner, F.S.; Engel, L.; Feist, T.; Gelb, M.H.; Haji, L.; Kim, D.; Liu, C.; Mueller, N.; Myler, P.J.; Reddy, J.T.; Sampson, J.N.; Subramanian, E.; Van Voorhis, W.C.; Worthey, E.; Zucker, F.; Hol, W.G. Heterologous expression ofproteins from Plasmodium falciparum: results from 1000 genes. Mol. Biochem. Parasitol., 2006, 148(2), 144-60.
98. Aguiar, J.C.; LaBaer, J.; Blair, P.L.; Shamailova, V.Y.; Koundinya, M.; Russell, J.A.; Huang, F.; Mar, W.; Anthony, R.M.; Witney, A.; Caruana, S.R.; Brizuela, L.; Sacci, J.B., Jr.; Hoffman, S.L.; Carucci, D.J. High-throughput generation of P. falciparumfunctional molecules by recombinational cloning. Genome Res., 2004, 14(10B), 2076-82.
99. Graslund, S.; Nordlund, P.; Weigelt, J.; Hallberg, B.M.; Bray, J.; Gileadi, O.; Knapp, S.; Oppermann, U.; Arrowsmith, C.; Hui, R.; Ming, J.; dhe-Paganon, S.; Park, H. W.; Savchenko, A.; Yee, A.; Edwards, A.; Vincentelli, R.; Cambillau, C.; Kim, R.; Kim, S.H.; Rao, Z.; Shi, Y.; Terwilliger, T.C.; Kim, C.Y.; Hung, L.W.; Waldo, G.S.; Peleg, Y.; Albeck, S.; Unger, T.; Dym, O.; Prilusky, J.; Sussman, J.L.; Stevens, R.C.; Lesley, S.A.; Wilson, I.A.; Joachimiak, A.; Collart, F.; Dementieva, I.; Donnelly, M.I.; Eschenfeldt, W.H.; Kim, Y.; Stols, L.; Wu, R.; Zhou, M.; Burley, S.K.; Emtage, J.S.; Sauder, J.M.; Thompson, D.; Bain, K.; Luz, J.; Gheyi, T.; Zhang, F.; Atwell, S.; Almo, S.C.; Bonanno, J.B.; Fiser, A.; Swaminathan, S.; Studier, F.W.; Chance, M.R.; Sali, A.; Acton, T.B.; Xiao, R.; Zhao, L.; Ma, L.C.; Hunt, J.F.; Tong, L.; Cunningham, K.; Inouye, M.; Anderson, S.; Janjua, H.; Shastry, R.; Ho, C.K.; Wang, D.; Wang, H.; Jiang, M.; Montelione, G.T.; Stuart, D.I.; Owens, R.J.; Daenke, S.; Schutz, A.; Heinemann, U.; Yokoyama, S.; Bussow, K.; Gunsalus, K.C. Protein production andpurification. Nat. Methods, 2008, 5(2), 135-46.
100. Rappuoli, R. Reverse vaccinology. Curr. Opin. Microbiol., 2000, 3(5), 445-50.
101. Sheridan, C. Vaccine market boosters. Nat. Biotechnol., 2009, 27(6), 499-501.
102. Giuliani, M.M.; Adu-Bobie, J.; Comanducci, M.; Arico, B.; Savino, S.; Santini, L.; Brunelli, B.; Bambini, S.; Biolchi, A.; Capecchi, B.; Cartocci, E.; Ciucchi, L.; Di Marcello, F.; Ferlicca, F.; Galli, B.; Luzzi, E.; Masignani, V.; Serruto, D.; Veggi, D.; Contorni, M.; Morandi, M.; Bartalesi, A.; Cinotti, V.; Mannucci, D.; Titta, F.; Ovidi, E.; Welsch, J.A.; Granoff, D.; Rappuoli, R.; Pizza, M. Auniversal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA, 2006, 103(29), 10834-9.
103. Bryan, J.T. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine, 2007, 25(16), 3001-6.
104. Porro, D.; Branduardi, P. Yeast cell factory: fishing for the best oneor engineering it? Microb. Cell Fact, 2009, 8, 51.
105. Gerngross, T.U. Advances in the production of human therapeuticproteins in yeasts and filamentous fungi. Nat. Biotechnol., 2004, 22(11), 1409-14.
106. Pass, R.F.; Zhang, C.; Evans, A.; Simpson, T.; Andrews, W.; Huang, M.L.; Corey, L.; Hill, J.; Davis, E.; Flanigan, C.; Cloud, G. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med., 2009, 360(12), 1191-9.
107. Alexander, J.; Bey, E.; Whitcutt, J.M.; Gear, J.H. Adaptation ofcells derived from human malignant tumours to growth in vitro. S. Afr. J. Med. Sci., 1976, 41(2), 89-98.
108. Monie, A.; Hung, C.F.; Roden, R.; Wu, T.C. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics, 2008, 2(1), 97-105.
109. Bright, R.A.; Carter, D.M.; Crevar, C.J.; Toapanta, F.R.; Steckbeck, J.D.; Cole, K.S.; Kumar, N.M.; Pushko, P.; Smith, G.; Tumpey, T.M.; Ross, T.M. Cross-clade protective immuneresponses to influenza viruses with H5N1 HA and NA elicited byan influenza virus-like particle. PLoS ONE, 2008, 3(1), e1501.
110. Wang, Y.; Tsai, Y.C.; Urena-Rivera, E.; Chen, J. Expression, purification and characterization of recombinant mitochondrialtopoisomerase II of kinetoplastid Crithidia fasciculata in High-fiveinsect cells. Protein Expr. Purif., 2008, 58(1), 122-31.
111. Pang, A.L.; Hashimoto, C.N.; Tam, L.Q.; Meng, Z.Q.; Hui, G.S.; Ho, W.K. In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodiumfalciparum merozoite surface protein 1 in the baculovirus-silkwormsystem. Infect. Immun., 2002, 70(6), 2772-9.
112. Weide, T.; Bockau, U.; Rave, A.; Herrmann, L.; Hartmann, M.W.A recombinase system facilitates cloning of expression cassettes in the ciliate Tetrahymena thermophila. BMC Microbiol., 2007, 7, 12.
113. Gaertig, J.; Gao, Y.; Tishgarten, T.; Clark, T.G.; Dickerson, H.W. Surface display of a parasite antigen in the ciliate Tetrahymenathermophila. Nat. Biotechnol, 1999, 17(5), 462-5.
114. Arya, R.; Bhattacharya, A.; Saini, K. S. Dictyostelium discoideum-a promising expression system for the production of eukaryoticproteins. FASEB J., 2008, 22(12), 4055-66.
115. Fasel, N.; Begdadi-Rais, C.; Bernard, M.; Bron, C.; Corradin, G.; Reymond, C.D. Dictyostelium discoideum as an expression host for the circumsporozoite protein of Plasmodium falciparum. Gene, 1992, 111(2), 157-63.
116. Sa, J.M.; Yamamoto, M.M.; Fernandez-Becerra, C.; de Azevedo, M.F.; Papakrivos, J.; Naude, B.; Wellems, T.E.; Del Portillo, H.A. Expression and function of pvcrt-o, a Plasmodium vivax orthologof pfcrt, in Plasmodium falciparum and Dictyostelium discoideum. Mol. Biochem. Parasitol., 2006, 150(2), 219-28.
117. Howe, D.K.; Mercier, C.; Messina, M.; Sibley, L.D. Expression of Toxoplasma gondii genes in the closely-related apicomplexanparasite Neospora caninum. Mol. Biochem. Parasitol., 1997, 86(1), 29-36.
118. Ramirez, J.R.; Gilchrist, K.; Robledo, S.; Sepulveda, J.C.; Moll, H.; Soldati, D.; Berberich, C. Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice. Vaccine, 2001, 20(3-4), 455-61.
119. Kucknoor, A.S.; Mundodi, V.; Alderete, J.F. Heterologous expression in Tritrichomonas foetus of functional Trichomonasvaginalis AP65 adhesin. BMC Mol. Biol., 2005, 6(1), 5.
120. Lee, W.M. Hepatitis B virus infection. N. Engl. J. Med., 1997, 337(24), 1733-45.
121. Lee, P.I.; Lee, C.Y. Practical considerations in converting fromplasma-derived to recombinant hepatitis B vaccines. BioDrugs, 1998, 10(1), 11-25.
122. Heermann, K.H.; Goldmann, U.; Schwartz, W.; Seyffarth, T.; Baumgarten, H.; Gerlich, W.H. Large surface proteins of hepatitisB virus containing the pre-s sequence. J. Virol., 1984, 52(2), 396-402.
123. Blumberg, B.S.; Gerstley, B.J.; Hungerford, D.A.; London, W.T.; Sutnick, A.I. A serum antigen (Australia antigen) in Down'ssyndrome, leukemia, and hepatitis. Ann Intern. Med., 1967, 66(5), 924-31.
124. Fukuda, Y.; Kokuryu, H.; Imura, H. Diagnosis of type B hepatitis. Rinsho Byori, 1990, 38(5), 573-7.
125. Stephenne, J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine, 1990, 8, S69-73; discussion S79-80.
126. Hardy, E.; Martinez, E.; Diago, D.; Diaz, R.; Gonzalez, D.; Herrera, L. Large-scale production of recombinant hepatitis Bsurface antigen from Pichia pastoris. J. Biotechnol., 2000, 77(2-3), 157-67.
127. Thierie, J. Modeling threshold phenomena, metabolic pathwaysswitches and signals in chemostat-cultivated cells: the Crabtreeeffect in Saccharomyces cerevisiae. J. Theor. Biol., 2004, 226(4), 483-501.
128. Kulkarni, P.S.; Raut, S.K.; Patki, P.S.; Phadke, M.A.; Jadhav, S.S.; Kapre, S.V.; Dhorje, S.P.; Godse, S.R. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenulapolymorpha in adults. Vaccine, 2006, 24(17), 3457-60.
129. Stephenne, J. Production in yeast versus mammalian cells of thefirst recombinant DNA human vaccine and its proved safety, efficacy, and economy: hepatitis B vaccine. Adv. Biotechnol. Processes, 1990, 14, 279-99.
130. Al-Faleh, F.Z.; Al-Jeffri, M.; Ramia, S.; Al-Rashed, R.; Arif, M.; Rezeig, M.; Al-Toraif, I.; Bakhsh, M.; Mishkkhas, A.; Makki, O.; Al-Freihi, H.; Mirdad, S.; AlJuma, A.; Yasin, T.; Al-Swailem, A.; Ayoola, A. Seroepidemiology of hepatitis B virus infection inSaudi children 8 years after a mass hepatitis B vaccinationprogramme. J. Infect., 1999, 38(3), 167-70.
131. Neurath, A.R.; Kent, S.B.; Strick, N.; Taylor, P.; Stevens, C.E. Hepatitis B virus contains pre-S gene-encoded domains. Nature, 1985, 315(6015), 154-6.
132. Itoh, Y.; Takai, E.; Ohnuma, H.; Kitajima, K.; Tsuda, F.; Machida, A.; Mishiro, S.; Nakamura, T.; Miyakawa, Y.; Mayumi, M. Asynthetic peptide vaccine involving the product of the pre-S(2)region of hepatitis B virus DNA: protective efficacy inchimpanzees. Proc. Natl. Acad. Sci. USA, 1986, 83(23), 9174-8.
133. Neurath, A.R.; Seto, B.; Strick, N. Antibodies to synthetic peptidesfrom the preS1 region of the hepatitis B virus (HBV) envelope(env) protein are virus-neutralizing and protective. Vaccine, 1989, 7(3), 234-6.
134. Yamada, T.; Iwabuki, H.; Kanno, T.; Tanaka, H.; Kawai, T.; Fukuda, H.; Kondo, A.; Seno, M.; Tanizawa, K.; Kuroda, S. Physicochemical and immunological characterization of hepatitis Bvirus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine, 2001, 19(23-24), 3154-63.
135. Imamura, T.; Araki, M.; Miyanohara, A.; Nakao, J.; Yonemura, H.; Ohtomo, N.; Matsubara, K. Expression of hepatitis B virus middle and large surface antigen genes in Saccharomyces cerevisiae. J. Virol., 1987, 61(11), 3543-9.
136. Kniskern, P.J.; Hagopian, A.; Burke, P.; Dunn, N.; Emini, E.A.; Miller, W.J.; Yamazaki, S.; Ellis, R.W. A candidate vaccine forhepatitis B containing the complete viral surface protein. Hepatology, 1988, 8(1), 82-7.
137. Mahanty, S.; Saul, A.; Miller, L.H. Progress in the development ofrecombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol., 2003, 206(Pt 21), 3781-8.
138. Schofield, L. Antidisease vaccines. Chem. Immunol., 2002, 80, 322-42.
139. Hoffman, S.L.; Oster, C.N.; Plowe, C.V.; Woollett, G.R.; Beier, J.C.; Chulay, J.D.; Wirtz, R.A.; Hollingdale, M.R.; Mugambi, M. Naturally acquired antibodies to sporozoites do not preventmalaria: vaccine development implications. Science, 1987, 237(4815), 639-42.
140. Angov, E.; Aufiero, B.M.; Turgeon, A.M.; Van Handenhove, M.; Ockenhouse, C.F.; Kester, K.E.; Walsh, D.S.; McBride, J.S.; Dubois, M.C.; Cohen, J.; Haynes, J.D.; Eckels, K. H.; Heppner, D.G.; Ballou, W. R.; Diggs, C. L.; Lyon, J. A. Development and preclinicalanalysis of a Plasmodium falciparum Merozoite SurfaceProtein-1(42) malaria vaccine. Mol. Biochem. Parasitol., 2003, 128(2), 195-204.
141. Keitel, W.A.; Kester, K.E.; Atmar, R.L.; White, A.C.; Bond, N.H.; Holland, C.A.; Krzych, U.; Palmer, D.R.; Egan, A.; Diggs, C.; Ballou, W.R.; Hall, B.F.; Kaslow, D. Phase I trial of tworecombinant vaccines containing the 19kd carboxy terminalfragment of Plasmodium falciparum merozoite surface protein 1(msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine, 1999, 18(5-6), 531-9.
142. Gordon, D.M.; McGovern, T.W.; Krzych, U.; Cohen, J.C.; Schneider, I.; LaChance, R.; Heppner, D.G.; Yuan, G.; Hollingdale, M.; Slaoui, M.; et al. Safety, immunogenicity, and efficacy of arecombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis., 1995, 171(6), 1576-85.
143. Lee, E.A.; Palmer, D.R.; Flanagan, K.L.; Reece, W.H.; Odhiambo, K.; Marsh, K.; Pinder, M.; Gravenor, M.B.; Keitel, W.A.; Kester, K.E.; Diggs, C.; Kaslow, D.; Apostolopoulos, V.; Ballou, W.R.; Hill, A.V.; Krzych, U.; Plebanski, M. Induction of T helper type 1and 2 responses to 19-kilodalton merozoite surface protein 1 invaccinated healthy volunteers and adults naturally exposed tomalaria. Infect. Immun., 2002, 70(3), 1417-21.
144. Graves, P.; Gelband, H. Vaccines for preventing malaria. CochraneDatabase Syst. Rev., 2003, 1, CD000129.
145. Genton, B.; Betuela, I.; Felger, I.; Al-Yaman, F.; Anders, R.F.; Saul, A.; Rare, L.; Baisor, M.; Lorry, K.; Brown, G.V.; Pye, D.; Irving, D.O.; Smith, T.A.; Beck, H.P.; Alpers, M.P. A recombinantblood-stage malaria vaccine reduces Plasmodium falciparumdensity and exerts selective pressure on parasite populations in aphase 1-2b trial in Papua New Guinea. J. Infect. Dis., 2002, 185(6), 820-7.
146. Oeuvray, C.; Bouharoun-Tayoun, H.; Gras-Masse, H.; Bottius, E.; Kaidoh, T.; Aikawa, M.; Filgueira, M.C.; Tartar, A.; Druilhe, P. Merozoite surface protein-3: a malaria protein inducing antibodiesthat promote Plasmodium falciparum killing by cooperation withblood monocytes. Blood, 1994, 84(5), 1594-602.
147. Hisaeda, H.; Saul, A.; Reece, J.J.; Kennedy, M.C.; Long, C.A.; Miller, L.H.; Stowers, A.W. Merozoite surface protein 3 andprotection against malaria in Aotus nancymai monkeys. J. Infect. Dis., 2002, 185(5), 657-64.
148. Anders, R.F.; Saul, A. Malaria vaccines. Parasitol. Today, 2000, 16(10), 444-7.
149. Anders, R.F.; Crewther, P.E.; Edwards, S.; Margetts, M.; Matthew, M.L.; Pollock, B.; Pye, D. Immunisation with recombinant AMA-1protects mice against infection with Plasmodium chabaudi. Vaccine, 1998, 16(2-3), 240-7.
150. Hodder, A.N.; Crewther, P.E.; Anders, R.F. Specificity of theprotective antibody response to apical membrane antigen 1. Infect. Immun., 2001, 69(5), 3286-94.
151. Kennedy, M.C.; Wang, J.; Zhang, Y.; Miles, A.P.; Chitsaz, F.; Saul, A.; Long, C. A.; Miller, L.H.; Stowers, A.W. In vitro studieswith recombinant Plasmodium falciparum apical membrane antigen1 (AMA1): production and activity of an AMA1 vaccine andgeneration of a multiallelic response. Infect. Immun., 2002, 70(12), 6948-60.
152. Inselburg, J.; Bathurst, I.C.; Kansopon, J.; Barr, P.J.; Rossan, R. Protective immunity induced in Aotus monkeys by a recombinantSERA protein of Plasmodium falciparum: further studies usingSERA 1 and MF75.2 adjuvant. Infect. Immun., 1993, 61(5), 2048-52.
153. Aoki, S.; Li, J.; Itagaki, S.; Okech, B.A.; Egwang, T.G.; Matsuoka, H.; Palacpac, N.M.; Mitamura, T.; Horii, T. Serine repeat antigen(SERA5) is predominantly expressed among the SERA multigenefamily of Plasmodium falciparum, and the acquired antibody titerscorrelate with serum inhibition of the parasite growth. J. Biol. Chem., 2002, 277(49), 47533-40.
154. Genton, B.; Al-Yaman, F.; Anders, R.; Saul, A.; Brown, G.; Pye, D.; Irving, D. O.; Briggs, W.R.; Mai, A.; Ginny, M.; Adiguma, T.; Rare, L.; Giddy, A.; Reber-Liske, R.; Stuerchler, D.; Alpers, M.P. Safety and immunogenicity of a three-component blood-stagemalaria vaccine in adults living in an endemic area of Papua NewGuinea. Vaccine, 2000, 18(23), 2504-11.
155. Berzins, K.; Perlmann, H.; Wahlin, B.; Ekre, H.P.; Hogh, B.; Petersen, E.; Wellde, B.; Schoenbechler, M.; Williams, J.; Chulay, J.; et al. Passive immunization of Aotus monkeys with humanantibodies to the Plasmodium falciparum antigen Pf155/RESA. Infect. Immun., 1991, 59(4), 1500-6.
156. Collins, W.E.; Anders, R.F.; Pappaioanou, M.; Campbell, G.H.; Brown, G.V.; Kemp, D.J.; Coppel, R.L.; Skinner, J.C.; Andrysiak, P.M.; Favaloro, J.M.; et al. Immunization of Aotus monkeys withrecombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature, 1986, 323(6085), 259-62.
157. Sim, B.K.; Chitnis, C.E.; Wasniowska, K.; Hadley, T.J.; Miller, L.H. Receptor and ligand domains for invasion of erythrocytes byPlasmodium falciparum. Science, 1994, 264(5167), 1941-4.
158. Jones, T.R.; Narum, D.L.; Gozalo, A.S.; Aguiar, J.; Fuhrmann, S.R.; Liang, H.; Haynes, J.D.; Moch, J.K.; Lucas, C.; Luu, T.; Magill, A.J.; Hoffman, S.L.; Sim, B.K. Protection of Aotusmonkeys by Plasmodium falciparum EBA-175 region II DNAprime-protein boost immunization regimen. J. Infect. Dis., 2001, 183(2), 303-312.
159. Gozar, M.M.; Muratova, O.; Keister, D.B.; Kensil, C.R.; Price, V.L.; Kaslow, D.C. Plasmodium falciparum: immunogenicity ofalum-adsorbed clinical-grade TBV25-28, a yeast-secreted malariatransmission-blocking vaccine candidate. Exp. Parasitol., 2001, 97(2), 61-9.
160. Malkin, E.M.; Durbin, A.P.; Diemert, D.J.; Sattabongkot, J.; Wu, Y.; Miura, K.; Long, C.A.; Lambert, L.; Miles, A. P.; Wang, J.; Stowers, A.; Miller, L.H.; Saul, A. Phase 1 vaccine trial of Pvs25H:a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine, 2005, 23(24), 3131-8.
161. Kaslow, D.C. Transmission-blocking vaccines. Chem. Immunol., 2002, 80, 287-307.
162. Patarroyo, M.E.; Romero, P.; Torres, M.L.; Clavijo, P.; Moreno, A.; Martinez, A.; Rodriguez, R.; Guzman, F.; Cabezas, E. Induction of protective immunity against experimental infectionwith malaria using synthetic peptides. Nature, 1987, 328(6131), 629-32.
163. Ghim, S.; Christensen, N.D.; Kreider, J.W.; Jenson, A.B. Comparison of neutralization of BPV-1 infection of C127 cells andbovine fetal skin xenografts. Int. J. Cancer, 1991, 49(2), 285-9.
164. Ghim, S.J.; Jenson, A.B.; Schlegel, R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intactvirions. Virology, 1992, 190(1), 548-52.
165. Culp, T.D.; Spatz, C.M.; Reed, C.A.; Christensen, N.D. Binding and neutralization efficiencies of monoclonal antibodies, Fabfragments, and scFv specific for L1 epitopes on the capsid ofinfectious HPV particles. Virology, 2007, 361(2), 435-46.
166. Hines, J.F.; Ghim, S.J.; Christensen, N.D.; Kreider, J.W.; Barnes, W.A.; Schlegel, R.; Jenson, A.B. Role of conformational epitopesexpressed by human papillomavirus major capsid proteins in theserologic detection of infection and prophylactic vaccination. Gynecol. Oncol., 1994, 55(1), 13-20.
167. Florin, L.; Becker, K.A.; Lambert, C.; Nowak, T.; Sapp, C.; Strand, D.; Streeck, R. E.; Sapp, M. Identification of a dynein interactingdomain in the papillomavirus minor capsid protein l2. J. Virol., 2006, 80(13), 6691-6.
168. Kamper, N.; Day, P.M.; Nowak, T.; Selinka, H.C.; Florin, L.; Bolscher, J.; Hilbig, L.; Schiller, J.T.; Sapp, M. A membranede stabilizing peptide in capsid protein L2 is required for egress ofpapillomavirus genomes from endosomes. J. Virol., 2006, 80(2), 759-68.
169. Gaukroger, J.M.; Chandrachud, L.M.; O'Neil, B.W.; Grindlay, G.J.; Knowles, G.; Campo, M.S. Vaccination of cattle with bovinepapillomavirus type 4 L2 elicits the production of virusneutralizing antibodies. J. Gen. Virol., 1996, 77(Pt 7), 1577-83.
170. Campo, M.S.; O'Neil, B.W.; Grindlay, G.J.; Curtis, F.; Knowles, G.; Chandrachud, L. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4prevents disease. Virology, 1997, 234(2), 261-6.
171. Knowles, G.; Grindlay, G.J.; Campo, M.S.; Chandrachud, L.M.; O'Neil, B.W. Linear B-cell epitopes in the N-terminus of L2 ofbovine papillomavirus type 4. Res. Vet. Sci., 1997, 62(3), 289-91.
172. Chandrachud, L.M.; Grindlay, G.J.; McGarvie, G.M.; O'Neil, B.W.; Wagner, E. R.; Jarrett, W.F.; Campo, M.S. Vaccination ofcattle with the N-terminus of L2 is necessary and sufficient forpreventing infection by bovine papillomavirus-4. Virology, 1995, 211(1), 204-8.
173. Baud, D.; Benyacoub, J.; Revaz, V.; Kok, M.; Ponci, F.; Bobst, M.; Curtiss, R., 3rd; De Grandi, P.; Nardelli-Haefliger, D. Immunogenicity against human papillomavirus type 16 virus-likeparticles is strongly enhanced by the PhoPc phenotype inSalmonella enterica serovar Typhimurium. Infect. Immun., 2004, 72(2), 750-6.
174. Baud, D.; Ponci, F.; Bobst, M.; De Grandi, P.; Nardelli-Haefliger, D. Improved efficiency of a Salmonella-based vaccine againsthuman papillomavirus type 16 virus-like particles achieved byusing a codon-optimized version of L1. J. Virol., 2004, 78(23), 12901-9.
175. Govan, V.A.; Christensen, N.D.; Berkower, C.; Jacobs, W.R., Jr.; Williamson, A. L. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene providesprotection from CRPV challenge. Vaccine, 2006, 2(12), 2087-93.
176. Warzecha, H.; Mason, H.S.; Lane, C.; Tryggvesson, A.; Rybicki, E.; Williamson, A.L.; Clements, J.D.; Rose, R.C. Oralimmunogenicity of human papillomavirus-like particles expressedin potato. J. Virol., 2003, 77(16), 8702-11.
177. Kohl, T.; Hitzeroth, II; Stewart, D.; Varsani, A.; Govan, V.A.; Christensen, N.D.; Williamson, A. L.; Rybicki, E. P. Plant produced cottontail rabbit papillomavirus L1 protein protectsagainst tumor challenge: a proof-of-concept study. Clin. Vaccine Immunol., 2006, 13(8), 845-53.
178. Kohl, T.O.; Hitzeroth, II; Christensen, N.D.; Rybicki, E.P. Expression of HPV-11 L1 protein in transgenic Arabidopsisthaliana and Nicotiana tabacum. BMC Biotechnol., 2007, 7, 56.
179. Biemelt, S.; Sonnewald, U.; Galmbacher, P.; Willmitzer, L.; Muller, M. Production of human papillomavirus type 16 virus-likeparticles in transgenic plants. J. Virol., 2003, 77(17), 9211-20.
180. Rose, R.C.; Lane, C.; Wilson, S.; Suzich, J.A.; Rybicki, E.; Williamson, A.L. Oral vaccination of mice with humanpapillomavirus virus-like particles induces systemic virusneutralizing antibodies. Vaccine, 1999, 17(17), 2129-35.
181. Zhou, J.; Sun, X.Y.; Stenzel, D.J.; Frazer, I.H. Expression ofvaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelialcells is sufficient for assembly of HPV virion-like particles. Virology, 1991, 185(1), 251-7.
182. Rose, R.C.; Bonnez, W.; Reichman, R.C.; Garcea, R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J. Virol., 1993, 67(4), 1936-44.
183. Kirnbauer, R.; Booy, F.; Cheng, N.; Lowy, D.R.; Schiller, J.T. Papillomavirus L1 major capsid protein self-assembles into viruslikeparticles that are highly immunogenic. Proc. Natl. Acad. Sci. USA, 1992, 89(24), 12180-4.
184. Hofmann, K.J.; Cook, J.C.; Joyce, J.G.; Brown, D.R.; Schultz, L.D.; George, H.A.; Rosolowsky, M.; Fife, K.H.; Jansen, K.U. Sequence determination of human papillomavirus type 6a andassembly of virus-like particles in Saccharomyces cerevisiae. Virology, 1995, 209(2), 506-18.
185. McLemore, M.R. Gardasil: Introducing the new humanpapillomavirus vaccine. Clin. J. Oncol. Nurs., 2006, 10(5), 559-60.
186. Treanor, J. Recombinant proteins produced in insect cells. Curr. Top. Microbiol. Immunol., 2009, 333, 211-25.
187. Wood, J.M. Standardization of inactivated influenza vaccine. In Textbook of influenza, Nicholson, K.G.; Webster, R.G.; Hay, A.J. Eds. Blackwell: London, 1998; pp 333-345.
188. Kost, T.A.; Condreay, J.P.; Jarvis, D.L. Baculovirus as versatilevectors for protein expression in insect and mammalian cells. Nat. Biotechnol., 2005, 23(5), 567-75.
189. Holtz, K.M.; Anderson, D.K.; Cox, M.M. Production of arecombinant influenza vaccine using the baculovirus expressionvector system. Bioprocess. J., 2003, 2, 25-32.
190. Cox, M.M.; Karl Anderson, D. Production of a novel influenzavaccine using insect cells: protection against drifted strains. Influenza Other. Resp. Viruses, 2007, 1(1), 35-40.
191. Palache, A.M.; Brands, R.; van Scharrenburg, G.J. Immunogenicity and reactogenicity of influenza subunit vaccines produced inMDCK cells or fertilized chicken eggs. J. Infect. Dis., 1997, 176(Suppl 1), S20-3.
192. Wang, K.; Holtz, K.M.; Anderson, K.; Chubet, R.; Mahmoud, W.; Cox, M.M. Expression and purification of an influenzahemagglutinin-one step closer to a recombinant protein-basedinfluenza vaccine. Vaccine, 2006, 24(12), 2176-85.
193. Quan, F.S.; Huang, C.; Compans, R.W.; Kang, S.M. Virus-likeparticle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol., 2007, 81(7), 3514-24.
194. Pushko, P.; Tumpey, T.M.; Bu, F.; Knell, J.; Robinson, R.; Smith, G. Influenza virus-like particles comprised of the HA, NA, and M1proteins of H9N2 influenza virus induce protective immuneresponses in BALB/c mice. Vaccine, 2005, 23(50), 5751-9.
195. Swayne, D.E.; Perdue, M.L.; Beck, J.R.; Garcia, M.; Suarez, D.L. Vaccines protect chickens against H5 highly pathogenic avianinfluenza in the face of genetic changes in field viruses overmultiple years. Vet. Microbiol., 2000, 74(1-2), 165-72.
196. Crawford, J.; Wilkinson, B.; Vosnesensky, A.; Smith, G.; Garcia, M.; Stone, H.; Perdue, M.L. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine, 1999, 17(18), 2265-74.
197. Johansson, B.E. Immunization with influenza A virushemagglutinin and neuraminidase produced in recombinantbaculovirus results in a balanced and broadened immune responsesuperior to conventional vaccine. Vaccine, 1999, 17(15-16), 2073-80.
198. Brett, I.C.; Johansson, B.E. Immunization against influenza Avirus: comparison of conventional inactivated, live-attenuated andrecombinant baculovirus produced purified hemagglutinin andneuraminidase vaccines in a murine model system. Virology, 2005, 339(2), 273-80.
199. Katz, J.M.; Lu, X.; Frace, A.M.; Morken, T.; Zaki, S.R.; Tumpey, T.M. Pathogenesis of and immunity to avian influenza A H5viruses. Biomed. Pharmacother., 2000, 54(4), 178-87.
200. Treanor, J.; Betts, R.; Powers, D.; Belshe, R.; Anderson, E.L.; Lakey, D.; Wright, P.; Wilkinson, B.; Smith, G. Evaluation ofrecombinant influenza virus hemagglutinins (HAs) expressed ininsect cells as influenza vaccines in humans. In: Options for thecontrol of influenza III, Brown, L.E.; Hampson, A.W.; Webster, R.G., Eds. Elsevier: Amsterdam, 1996; pp 677-682.
201. Powers, D.C.; Smith, G.E.; Anderson, E.L.; Kennedy, D.J.; Hackett, C.S.; Wilkinson, B.E.; Volvovitz, F.; Belshe, R.B.; Treanor, J.J. Influenza A virus vaccines containing purifiedrecombinant H3 hemagglutinin are well tolerated and induceprotective immune responses in healthy adults. J. Infect. Dis., 1995, 171(6), 1595-9.
202. Lakey, D.L.; Treanor, J.J.; Betts, R.F.; Smith, G.E.; Thompson, J.; Sannella, E.; Reed, G.; Wilkinson, B.E.; Wright, P.F. Recombinantbaculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis., 1996, 174(4), 838-41.
203. Cox, M.M.; Hollister, J.R. FluBlok, a next generation influenzavaccine manufactured in insect cells. Biologicals, 2009, 37(3), 182-9.
204. Bridges, C.B.; Fukuda, K.; Uyeki, T.M.; Cox, N.J.; Singleton, J.A. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWRRecomm. Rep., 2002, 51(RR-3), 1-31.
205. Cox, M.M.; Patriarca, P.A.; Treanor, J. FluBlok, a recombinanthemagglutinin influenza vaccine. Influenza Other. Resp. Viruses, 2008, 2(6), 211-9.
206. Friedlander, A.M.; Little, S.F. Advances in the development ofnext-generation anthrax vaccines. Vaccine, 2009, 27 (Suppl 4), D28-32.
207. Watson, D.W.; Cromartie, W.J.; et al. Studies on infection withBacillus anthracis; chemical and immunological properties of theprotective antigen in crude extracts of skin lesions of B. anthracis. J. Infect. Dis., 1947, 80(1), 28-40.
208. Turnbull, P.C.; Leppla, S.H.; Broster, M.G.; Quinn, C.P.; Melling, J. Antibodies to anthrax toxin in humans and guinea pigs and theirrelevance to protective immunity. Med. Microbiol. Immunol., 1988, 177(5), 293-303.
209. Taft, S.C.; Weiss, A.A. Neutralizing activity of vaccine- inducedantibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol., 2008, 15(1), 71-5.
210. Whiting, G.C.; Rijpkema, S.; Adams, T.; Corbel, M.J. Characterisation of adsorbed anthrax vaccine by two-dimensionalgel electrophoresis. Vaccine, 2004, 22(31-32), 4245-51.
211. Little, S.F.; Knudson, G.B. Comparative efficacy of Bacillusanthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun., 1986, 52(2), 509-12.
212. Singh, Y.; Ivins, B.E.; Leppla, S.H. Study of immunization againstanthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect. Immun., 1998, 66(7), 3447-8.
213. Iacono-Connors, L.C.; Welkos, S.L.; Ivins, B.E.; Dalrymple, J.M. Protection against anthrax with recombinant virus-expressedprotective antigen in experimental animals. Infect. Immun., 1991, 59(6), 1961-5.
214. Yin, Y.; Zhang, J.; Dong, D.; Liu, S.; Guo, Q.; Song, X.; Li, G.; Fu, L.; Xu, J.; Chen, W. Chimeric hepatitis B virus core particlescarrying an epitope of anthrax protective antigen induce protectiveimmunity against Bacillus anthracis. Vaccine, 2008, 26(46), 5814-21.
215. Lee, J.S.; Hadjipanayis, A.G.; Welkos, S.L. Venezuelan equineencephalitis virus-vectored vaccines protect mice against anthraxspore challenge. Infect. Immun., 2003, 71(3), 1491-6.
216. Campbell, J.D.; Clement, K.H.; Wasserman, S.S.; Donegan, S.; Chrisley, L.; Kotloff, K.L. Safety, reactogenicity andimmunogenicity of a recombinant protective antigen anthraxvaccine given to healthy adults. Hum. Vaccin., 2007, 3(5), 205-11.
217. Gorse, G.J.; Keitel, W.; Keyserling, H.; Taylor, D. N.; Lock, M.; Alves, K.; Kenner, J.; Deans, L.; Gurwith, M. Immunogenicity andtolerance of ascending doses of a recombinant protective antigen(rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine, 2006, 24(33-34), 5950-9.
218. Cartwright, K.; Morris, R.; Rumke, H.; Fox, A.; Borrow, R.; Begg, N.; Richmond, P.; Poolman, J. Immunogenicity and reactogenicityin UK infants of a novel meningococcal vesicle vaccine containingmultiple class 1 (PorA) outer membrane proteins. Vaccine, 1999, 17(20-21), 2612-9.
219. Pettersson, A.; Prinz, T.; Umar, A.; van der Biezen, J.; Tommassen, J. Molecular characterization of LbpB, the second lactoferrin binding protein of Neisseria meningitidis. Mol. Microbiol., 1998, 27(3), 599-610.
220. Ala'Aldeen, D.A.; Borriello, S.P. The meningococcal transferrin binding proteins 1 and 2 are both surface exposed and generatebactericidal antibodies capable of killing homologous andheterologous strains. Vaccine, 1996, 14(1), 49-53.
221. Legrain, M.; Findeli, A.; Villeval, D.; Quentin-Millet, M.J.; Jacobs, E. Molecular characterization of hybrid Tbp2 proteins from Neisseria meningitidis. Mol. Microbiol., 1996, 19(1), 159-69.
222. Rokbi, B.; Mignon, M.; Maitre-Wilmotte, G.; Lissolo, L.; Danve, B.; Caugant, D.A.; Quentin-Millet, M.J. Evaluation of recombinanttransferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodiesagainst a genetically diverse collection of serogroup B strains. Infect. Immun., 1997, 65(1), 55-63.
223. Cherry, J.D. Historical review of pertussis and the classicalvaccine. J Infect Dis, 1996, 174(Suppl 3), S259-63.
224. Gustafsson, L.; Hallander, H.O.; Olin, P.; Reizenstein, E.; Storsaeter, J.A controlled trial of a two-component acellular, a five componenta cellular, and a whole-cell pertussis vaccine. N. Engl. J. Med., 1996, 334(6), 349-55.
225. Di Tommaso, A.; Bartalini, M.; Peppoloni, S.; Podda, A.; Rappuoli, R.; De Magistris, M.T. Acellular pertussis vaccinescontaining genetically detoxified pertussis toxin induce long-lastinghumoral and cellular responses in adults. Vaccine, 1997, 15(11), 1218-24.
226. Dolin, P.J.; Raviglione, M.C.; Kochi, A. Global tuberculosis incidence and mortality during 1990-2000. Bull. World HealthOrgan., 1994, 72(2), 213-20.
227. Nolan, C.M. Nosocomial multidrug-resistant tuberculosis-globalspread of the third epidemic. J. Infect. Dis., 1997, 176(3), 748-51.
228. Slobbe, L.; Lockhart, E.; O'Donnell, M.A.; MacKintosh, C.; DeLisle, G.; Buchan, G. An in vivo comparison of bacillus Calmette-Guerin (BCG) and cytokine-secreting BCG vaccines. Immunology, 1999, 96(4), 517-23.
229. Hess, J.; Kaufmann, S.H. Live antigen carriers as tools forimproved anti-tuberculosis vaccines. FEMS Immunol. Med. Microbiol., 1999, 23(2), 165-73.
230. Holmgren, J.; Svennerholm, A.M.; Lonnroth, I.; Fall-Persson, M.; Markman, B.; Lundbeck, H. Development of improved choleravaccine based on subunit toxoid. Nature, 1977, 269(5629), 602-4.
231. Lebens, M.; Shahabi, V.; Backstrom, M.; Houze, T.; Lindblad, N.; Holmgren, J. Synthesis of hybrid molecules between heat-labileenterotoxin and cholera toxin B subunits: potential for use in abroad-spectrum vaccine. Infect. Immun., 1996, 64(6), 2144-50.
232. von Specht, B.U.; Lucking, H.C.; Blum, B.; Schmitt, A.; Hungerer, K.D.; Domdey, H. Safety and immunogenicity of a Pseudomonasaeruginosa outer membrane protein I vaccine in human volunteers. Vaccine, 1996, 14(12), 1111-7.
233. Matthews-Greer, J.M.; Gilleland, H.E., Jr. Outer membrane proteinF (porin) preparation of Pseudomonas aeruginosa as a protectivevaccine against heterologous immunotype strains in a burnedmouse model. J. Infect. Dis., 1987, 155(6), 1282-91.
234. Sawa, T.; Yahr, T.L.; Ohara, M.; Kurahashi, K.; Gropper, M.A.; Wiener-Kronish, J.P.; Frank, D.W. Active and passiveimmunization with the Pseudomonas V antigen protects againsttype III intoxication and lung injury. Nat. Med., 1999, 5(4), 392-8.
235. Gabelsberger, J.; Knapp, B.; Bauersachs, S.; Enz, U.I.; von Specht, B.U.; Domdey, H. A hybrid outer membrane protein antigen forvaccination against Pseudomonas aeruginosa. Behring Inst. Mitt., 1997, 98, 302-14.
236. Knapp, B.; Hundt, E.; Lenz, U.; Hungerer, K.D.; Gabelsberger, J.; Domdey, H.; Mansouri, E.; Li, Y.; von Specht, B.U. A recombinanthybrid outer membrane protein for vaccination againstPseudomonas aeruginosa. Vaccine, 1999, 17(13-14), 1663-6.
237. Kapikian, A.Z.; Mitchell, R.H.; Chanock, R.M.; Shvedoff, R.A.; Stewart, C.E. An epidemiologic study of altered clinical reactivityto respiratory syncytial (RS) virus infection in children previouslyvaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol., 1969, 89(4), 405-21.
238. Corvaia, N.; Tournier, P.; Nguyen, T.N.; Haeuw, J.F.; Power, U.F.; Binz, H.; Andreoni, C. Challenge of BALB/c mice with respiratorysyncytial virus does not enhance the Th2 pathway induced afterimmunization with a recombinant G fusion protein, BBG2NA, inaluminum hydroxide. J. Infect. Dis., 1997, 176(3), 560-9.
239. Homa, F.L.; Brideau, R.J.; Lehman, D.J.; Thomsen, D.R.; Olmsted, R.A.; Wathen, M.W. Development of a novel subunit vaccine thatprotects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3. J. Gen. Virol., 1993, 74(Pt9), 1995-9.
240. Pass, R.F.; Duliege, A.M.; Boppana, S.; Sekulovich, R.; Percell, S.; Britt, W.; Burke, R.L. A subunit cytomegalovirus vaccine based onrecombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis., 1999, 180(4), 970-5.
241. Palella, F.J., Jr.; Delaney, K.M.; Moorman, A.C.; Loveless, M.O.; Fuhrer, J.; Satten, G.A.; Aschman, D.J.; Holmberg, S.D. Decliningmorbidity and mortality among patients with advanced humanimmuno deficiency virus infection. HIV Outpatient StudyInvestigators. N. Engl. J. Med., 1998, 338(13), 853-60.
242. Kelleher, A.D.; Roggensack, M.; Jaramillo, A.B.; Smith, D.E.; Walker, A.; Gow, I.; McMurchie, M.; Harris, J.; Patou, G.; Cooper, D.A. Safety and immunogenicity of a candidate therapeuticvaccine, p24 virus-like particle, combined with zidovudine, inasymptomatic subjects. Community HIV Research NetworkInvestigators. AIDS, 1998, 12(2), 175-82.
243. Suzue, K.; Young, R.A. Adjuvant-free hsp70 fusion protein systemelicits humoral and cellular immune responses to HIV-1 p24. J. Immunol., 1996, 156(2), 873-9.
244. Gringeri, A.; Santagostino, E.; Muca-Perja, M.; Le Buanec, H.; Bizzini, B.; Lachgar, A.; Zagury, J.F.; Rappaport, J.; Burny, A.; Gallo, R. C.; Zagury, D. Tat toxoid as a component of a preventivevaccine in seronegative subjects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1999, 20(4), 371-5.
245. Stanberry, L.R.; Bernstein, D.I.; Burke, R.L.; Pachl, C.; Myers, M.G. Vaccination with recombinant herpes simplex virusglycoproteins: protection against initial and recurrent genitalherpes. J. Infect. Dis., 1987, 155(5), 914-20.
246. Berman, P.W.; Gregory, T.; Crase, D.; Lasky, L.A. Protection fromgenital herpes simplex virus type 2 infection by vaccination withcloned type 1 glycoprotein D. Science, 1985, 227(4693), 1490-2.
247. Myc, L.A.; Gamian, A.; Myc, A. Cancer vaccines. Any future?Arch. Immunol. Ther. Exp. (Warsz), 2011, 59(4), 249-59.
248. Waldmann, T.A. Immunotherapy: past, present and future. Nat. Med., 2003, 9(3), 269-77.
249. Paul, S.; Acres, B.; Limacher, J.M.; Bonnefoy, J.Y. Cancervaccines: challenges and outlook in the field. IDrugs, 2007, 10(5), 324-8.
250. Renkvist, N.; Castelli, C.; Robbins, P.F.; Parmiani, G. A listing ofhuman tumor antigens recognized by T cells. Cancer Immunol. Immunother., 2001, 50(1), 3-15.
251. Huang, C.J.; Lowe, A.J.; Batt, C.A. Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market. Appl. Microbiol. Biotechnol., 2010, 87(2), 401-10.
252. Goldman, B.; DeFrancesco, L. The cancer vaccine roller coaster. Nat. Biotechnol., 2009, 27(2), 129-39.
253. Bradbury, J. Vaccine against breast and ovarian cancer still on thehorizon. Mol. Med. Today, 2000, 6(10), 378.
254. Peled, N.; Oton, A.B.; Hirsch, F.R.; Bunn, P. MAGE A3 antigenspecific cancer immunotherapeutic. Immunotherapy, 2009, 1(1), 19-25.
255. Marchand, M.; Punt, C.J.; Aamdal, S.; Escudier, B.; Kruit, W.H.; Keilholz, U.; Hakansson, L.; van Baren, N.; Humblet, Y.; Mulders, P.; Avril, M.F.; Eggermont, A.M.; Scheibenbogen, C.; Uiters, J.; Wanders, J.; Delire, M.; Boon, T.; Stoter, G. Immunisation ofmetastatic cancer patients with MAGE-3 protein combined withadjuvant SBAS-2: a clinical report. Eur. J. Cancer, 2003, 39(1), 70-7.
256. Gridelli, C.; Rossi, A.; Maione, P.; Ferrara, M.L.; Castaldo, V.; Sacco, P.C. Vaccines for the treatment of non-small cell lungcancer: a renewed anticancer strategy. Oncologist, 2009, 14(9), 909-20.
257. Jungbluth, A.A.; Chen, Y.T.; Stockert, E.; Busam, K.J.; Kolb, D.; Iversen, K.; Coplan, K.; Williamson, B.; Altorki, N.; Old, L. J. Immunohistochemical analysis of NY-ESO-1 antigen expression innormal and malignant human tissues. Int. J. Cancer, 2001, 92(6), 856-60.
258. Davis, I.D.; Chen, W.; Jackson, H.; Parente, P.; Shackleton, M.; Hopkins, W.; Chen, Q.; Dimopoulos, N.; Luke, T.; Murphy, R.; Scott, A.M.; Maraskovsky, E.; McArthur, G.; MacGregor, D.; Sturrock, S.; Tai, T.Y.; Green, S.; Cuthbertson, A.; Maher, D.; Miloradovic, L.; Mitchell, S.V.; Ritter, G.; Jungbluth, A.A.; Chen, Y.T.; Gnjatic, S.; Hoffman, E. W.; Old, L.J.; Cebon, J.S. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvantinduces broad integrated antibody and CD4(+) and CD8(+) T cellresponses in humans. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10697-702.
259. Gnjatic, S.; Nishikawa, H.; Jungbluth, A.A.; Gure, A.O.; Ritter, G.; Jager, E.; Knuth, A.; Chen, Y.T.; Old, L.J. NY-ESO-1: review ofan immunogenic tumor antigen. Adv. Cancer Res., 2006, 95, 1-30.
260. Mukhopadhyay, A.; Bhatia, P.K.; Majumdar, S.S. Preliminarystudies with recombinant chorionic gonadotropin beta-subunitproduced in Escherichia coli for use as an antigen in a birth controlvaccine. Am. J. Reprod. Immunol., 1998, 39(3), 172-82.
261. Gordon, D.M. Use of novel adjuvants and delivery systems toimprove the humoral and cellular immune response to malariavaccine candidate antigens. Vaccine, 1993, 11(5), 591-3.
262. Daly, T.M.; Long, C.A. Influence of adjuvants on protectioninduced by a recombinant fusion protein against malarial infection. Infect. Immun., 1996, 64(7), 2602-8.
263. Coeshott, C.M.; Smithson, S.L.; Verderber, E.; Samaniego, A.; Blonder, J.M.; Rosenthal, G.J.; Westerink, M.A. Pluronic F127-based systemic vaccine delivery systems. Vaccine, 2004, 22(19), 2396-405.
264. Kim, S.H.; Park, S.A.; Kim, H.K.; Cho, Y.J.; Kim, K.S.; Kim, Y.H.; Chun, J.H.; Lee, N.G. Enhancement of the immune responsesof mice to Bacillus anthracis protective antigen by CIA07combined with alum. Arch. Pharm. Res., 2008, 31(11), 1385-92.
265. Chabot, D.J.; Scorpio, A.; Tobery, S.A.; Little, S.F.; Norris, S.L.; Friedlander, A.M. Anthrax capsule vaccine protects againstexperimental infection. Vaccine, 2004, 23(1), 43-7.
266. Gaur, R.; Gupta, P.K.; Banerjea, A.C.; Singh, Y. Effect of nasalimmunization with protective antigen of Bacillus anthracis onprotective immune response against anthrax toxin. Vaccine, 2002, 20(21-22), 2836-9.
267. Boyaka, P.N.; Tafaro, A.; Fischer, R.; Leppla, S.H.; Fujihashi, K.; McGhee, J.R. Effective mucosal immunity to anthrax: neutralizinganti bodies and Th cell responses following nasal immunizationwith protective antigen. J. Immunol., 2003, 170(11), 5636-43.
268. Flick-Smith, H.C.; Eyles, J.E.; Hebdon, R.; Waters, E.L.; Beedham, R.J.; Stagg, T.J.; Miller, J.; Alpar, H.O.; Baillie, L.W.; Williamson, E.D. Mucosal or parenteral administration of microspherea ssociated Bacillus anthracis protective antigen protects againstanthrax infection in mice. Infect. Immun., 2002, 70(4), 2022-8.
269. Sloat, B.R.; Cui, Z. Strong mucosal and systemic immunitiesinduced by nasal immunization with anthrax protective antigenprotein incorporated in liposome-protamine-DNA particles. Pharm. Res., 2006, 23(2), 262-9.
270. Saul, A. Kinetic constraints on the development of a malariavaccine. Parasite Immunol., 1987, 9(1), 1-9.
271. Cox, J.C.; Sjolander, A.; Barr, I.G. ISCOMs and other saponinbased adjuvants. Adv. Drug Deliv. Rev., 1998, 32(3), 247-271.
272. Shirodkar, S.; Hutchinson, R.L.; Perry, D.L.; White, J.L.; Hem, S.L. Aluminum compounds used as adjuvants in vaccines. Pharm. Res., 1990, 7(12), 1282-8.
273. Nash, A.D.; Lofthouse, S.A.; Barcham, G.J.; Jacobs, H.J.; Ashman, K.; Meeusen, E.N.; Brandon, M.R.; Andrews, A.E. Recombinantcytokines as immunological adjuvants. Immunol. Cell Biol., 1993, 71(Pt 5), 367-79.
274. Freytag, L.C.; Clements, J.D. Bacterial toxins as mucosaladjuvants. Curr. Top. Microbiol. Immunol., 1999, 236, 215-36.
275. Aucouturier, J.; Dupuis, L.; Deville, S.; Ascarateil, S.; Ganne, V. Montanide ISA 720 and 51: a new generation of water in oilemulsions as adjuvants for human vaccines. Expert Rev. Vaccines, 2002, 1(1), 111-8.
276. Palmer, K.E.; Jenson, A.B.; Kouokam, J.C.; Lasnik, A.B.; Ghim, S.J. Recombinant vaccines for the prevention of humanpapillomavirus infection and cervical cancer. Exp. Mol. Pathol., 2009, 86(3), 224-33.
277. Stanley, M.; Gissmann, L.; Nardelli-Haefliger, D. Immunobiology of human papillomavirus infection and vaccination -implications for second generation vaccines. Vaccine, 2008, 26(Suppl 10), K62-7.
278. Schiller, J.T.; Castellsague, X.; Villa, L.L.; Hildesheim, A. Anupdate of prophylactic human papillomavirus L1 virus-like particlevaccine clinical trial results. Vaccine, 2008, 26(Suppl 10), K53-61.
279. Bonnez, W. Human papillomavirus vaccine-recent results andfuture developments. Curr. Opin. Pharmacol., 2007, 7(5), 470-7.
280. Jung, J.; Kasuya, T.; Tanizawa, K.; Kuroda, S. [Bio-nanocapsules for in vivo pinpoint drug delivery]. Yakugaku Zasshi, 2007, 127(5), 797-805.
281. Jung, J.; Matsuzaki, T.; Tatematsu, K.; Okajima, T.; Tanizawa, K.; Kuroda, S. Bio-nanocapsule conjugated with liposomes for in vivopinpoint delivery of various materials. J. Control Release, 2008, 126(3), 255-64.
282. Kasuya, T.; Jung, J.; Kinoshita, R.; Goh, Y.; Matsuzaki, T.; Iijima, M.; Yoshimoto, N.; Tanizawa, K.; Kuroda, S. Bio-nanocapsuleliposomeconjugates for in vivo pinpoint drug and gene delivery. Methods Enzymol., 2009, 464, 147-66.
283. Fujisawa, Y.; Kuroda, S.; Van Eerd, P.M.; Schellekens, H.; Kakinuma, A. Protective efficacy of a novel hepatitis B vaccineconsisting of M (pre-S2 + S) protein particles (a third generationvaccine). Vaccine, 1990, 8(3), 192-8.
284. Kuroda, S.; Fujisawa, Y.; Iino, S.; Akahane, Y.; Suzuki, H. Induction of protection level of anti-pre-S2 antibodies in humansimmunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine, 1991, 9(3), 163-9.
285. Jung, J.; Iijima, M.; Yoshimoto, N.; Sasaki, M.; Niimi, T.; Tatematsu, K.; Jeong, S.Y.; Choi, E.K.; Tanizawa, K.; Kuroda, S. Efficient and rapid purification of drug-and gene-carrying bionanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae. Protein Expr. Purif., 2011, 78(2), 149-55.
286. Marion, P.L.; Salazar, F.H.; Alexander, J.J.; Robinson, W.S. Polypeptides of hepatitis B virus surface antigen produced by ahepatoma cell line. J. Virol., 1979, 32(3), 796-802.
287. Neurath, A.R.; Kent, S.B.; Strick, N.; Parker, K. Identification and chemical synthesis of a host cell receptor binding site on hepatitisB virus. Cell, 1986, 46(3), 429-36.
288. Michel, M.L.; Mancini, M.; Sobczak, E.; Favier, V.; Guetard, D.; Bahraoui, E.M.; Tiollais, P. Induction of anti-humanimmunodeficiency virus (HIV) neutralizing antibodies in rabbitsimmunized with recombinant HIV-hepatitis B surface antigenparticles. Proc. Natl. Acad. Sci. USA, 1988, 85(21), 7957-61.
289. Varsani, A.; Williamson, A.L.; Rose, R.C.; Jaffer, M.; Rybicki, E.P. Expression of Human papillomavirus type 16 major capsidprotein in transgenic Nicotiana tabacum cv. Xanthi. Arch. Virol., 2003, 148(9), 1771-86.
290. Maclean, J.; Koekemoer, M.; Olivier, A.J.; Stewart, D.; Hitzeroth, II; Rademacher, T.; Fischer, R.; Williamson, A.L.; Rybicki, E.P. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of differentHPV-16 L1 gene variants and different cell-compartmentlocalization. J. Gen. Virol., 2007, 88(Pt 5), 1460-9.
291. Mason, H.S.; Warzecha, H.; Mor, T.; Arntzen, C.J. Edible plantvaccines: applications for prophylactic and therapeutic molecularmedicine. Trends Mol. Med., 2002, 8(7), 324-9.
292. Rybicki, E.P. Plant-produced vaccines: promise and reality. DrugDiscov. Today, 2009, 14(1-2), 16-24.
293. Meyer, A.L.; Benson, J.M.; Gienapp, I.E.; Cox, K.L.; Whitacre, C.C. Suppression of murine chronic relapsing experimentalautoimmune encephalomyelitis by the oral administration ofmyelin basic protein. J. Immunol., 1996, 157(9), 4230-8.
294. Sato, Y.; Kimura, M.; Fukumi, H. Development of a pertussiscomponent vaccine in Japan. Lancet, 1984, 1(8369), 122-6.
295. Murdin, A.D.; Su, H.; Klein, M.H.; Caldwell, H.D. Poliovirushybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydiatrachomatis elicit broadly cross-reactive C. trachomatisneutralizingantibodies. Infect. Immun., 1995, 63(3), 1116-21.
296. Sun, J.B.; Rask, C.; Olsson, T.; Holmgren, J.; Czerkinsky, C. Treatment of experimental autoimmune encephalomyelitis byfeeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA, 1996, 93(14), 7196-201.
297. Moldoveanu, Z.; Porter, D.C.; Lu, A.; McPherson, S.; Morrow, C.D. Immune responses induced by administration of encapsidatedpoliovirus replicons which express HIV-1 gag and envelopeproteins. Vaccine, 1995, 13(11), 1013-22.
298. Nagler-Anderson, C.; Bober, L.A.; Robinson, M.E.; Siskind, G.W.; Thorbecke, G.J. Suppression of type II collagen-induced arthritisby intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci. USA, 1986, 83(19), 7443-6.
299. Tarkowski, A.; Sun, J.B.; Holmdahl, R.; Holmgren, J.; Czerkinsky, C. Treatment of experimental autoimmune arthritis by nasaladministration of a type II collagen-cholera toxoid conjugatevaccine. Arthritis Rheum., 1999, 42(8), 1628-34.
300. Trentham, D.E.; Dynesius-Trentham, R.A.; Orav, E.J.; Combitchi, D.; Lorenzo, C.; Sewell, K.L.; Hafler, D.A.; Weiner, H.L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science, 1993, 261(5129), 1727-30.
301. Tan, L.U.; Fahim, R.E.; Jackson, G.; Phillips, K.; Wah, P.; Alkema, D.; Zobrist, G.; Herbert, A.; Boux, L.; Chong, P.; et al. A novelprocess for preparing an acellular pertussis vaccine composed ofnon-pyrogenic toxoids of pertussis toxin and filamentoushemagglutinin. Mol. Immunol., 1991, 28(3), 251-5.
302. Valenzuela, P.; Coit, D.; Medina-Selby, M.A.; Kuo, C.H.; VanNest, G.; Burke, R.L.; Bull, P.; Urdea, M.S.; Graves, P.V. Antigenengineering in yeast: Synthesis and assembly of hybrid hepatitis Bsurface antigen-Herpes simplex 1 gD particles. Nature Biotechnol., 1985, 3, 323-326.
303. Pumpens, P.; Grens, E. Hepatitis B core particles as a universaldisplay model: a structure-function basis for development. FEBSLett., 1999, 442(1), 1-6.
304. Novak, M.J.; Smythies, L.E.; McPherson, S.A.; Smith, P.D.; Morrow, C.D. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immuneresponse. Vaccine, 1999, 17(19), 2384-91.
305. Haynes, J.R.; Cunningham, J.; von Seefried, A.; Lennick, M.; Garvin, R.T.; Shen, S.-H. Development of a geneticallyengineered, candidate polio vaccine employing the self-assemblingproperties of the tobacco mosaic virus coat protein. NatureBiotechnol., 1986, 4, 637-641.
306. Modelska, A.; Dietzschold, B.; Sleysh, N.; Fu, Z.F.; Steplewski, K.; Hooper, D.C.; Koprowski, H.; Yusibov, V. Immunizationagainst rabies with plant-derived antigen. Proc. Natl. Acad. Sci. USA, 1998, 95(5), 2481-5.
307. Carbonetti, N.H.; Irish, T.J.; Chen, C.H.; O'Connell, C.B.; Hadley, G.A.; McNamara, U.; Tuskan, R.G.; Lewis, G.K. Intracellulardelivery of a cytolytic T-lymphocyte epitope peptide by pertussistoxin to major histocompatibility complex class I withoutinvolvement of the cytosolic class I antigen processing pathway. Infect. Immun., 1999, 67(2), 602-7.
308. Guermonprez, P.; Ladant, D.; Karimova, G.; Ullmann, A.; Leclerc, C. Direct delivery of the Bordetella pertussis adenylate cyclasetoxin to the MHC class I antigen presentation pathway. J. Immunol., 1999, 162(4), 1910-6.
309. Doling, A.M.; Ballard, J.D.; Shen, H.; Krishna, K.M.; Ahmed, R.; Collier, R.J.; Starnbach, M.N. Cytotoxic T-lymphocyte epitopesfused to anthrax toxin induce protective antiviral immunity. Infect. Immun., 1999, 67(7), 3290-6.
310. Sandvig, K.; Garred, O.; Prydz, K.; Kozlov, J.V.; Hansen, S.H.; van Deurs, B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature, 1992, 358(6386), 510-2.
311. Noakes, K.L.; Teisserenc, H.T.; Lord, J.M.; Dunbar, P.R.; Cerundolo, V.; Roberts, L.M. Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. FEBS Lett., 1999, 453(1-2), 95-9.
312. Fleischmann, R.M.; Baumgartner, S.W.; Tindall, E.A.; Weaver, A.L.; Moreland, L.W.; Schiff, M.H.; Martin, R.W.; Spencer-Green, G.T. Response to etanercept (Enbrel) in elderly patients withrheumatoid arthritis: a retrospective analysis of clinical trial results. J. Rheumatol., 2003, 30(4), 691-6.
313. Baumgartner, S.W.; Fleischmann, R.M.; Moreland, L.W.; Schiff, M.H.; Markenson, J.; Whitmore, J.B. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versusestablished disease: improvement in disability. J. Rheumatol., 2004, 31(8), 1532-7.
314. Fayolle, C.; Ladant, D.; Karimova, G.; Ullmann, A.; Leclerc, C. Therapy of murine tumors with recombinant Bordetella pertussisadenylate cyclase carrying a cytotoxic T cell epitope. J. Immunol., 1999, 162(7), 4157-62.